Merck KGaA, Darmstadt, Germany, a leading science and technology company, has adopted Quris’ Bio-AI clinical prediction platform as part of its drug development pipeline.

Selected preclinical small molecule candidates will now be tested through the Quris-AI platform prior to initiating clinical trials. This follows a successful two-year validation study with Merck KGaA, Darmstadt, Germany, in which Quris-AI delivered a significantly higher accuracy in detecting drug-induced liver injury (DILI) compared to existing safety prediction approaches, potentially reducing reliance on animal testing.

Quris-AI’s drug safety prediction platform integrates advanced AI, machine learning, generative models, patient-on-chip technology, and proprietary data to predict potential drug- induced toxicities better. It is expected to improve safety predictions, speed up time to market, and ultimately enhance success rates.

“Thanks to technology breakthroughs, we can confirm the viability and safety of drug candidates well before they reach the clinical testing phase, reducing unnecessary risks and focusing resources, time, and budget on the drugs with the most potential,” said Dr. Isaac Bentwich, CEO of Quris-AI. “In our mission to get safe, effective drugs to patients faster, we are working hand-in-hand with leaders across the global pharmaceutical industry to drive the next era of AI-based drug discovery, development, and safety.”